<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05116228</url>
  </required_header>
  <id_info>
    <org_study_id>2015-002156-27</org_study_id>
    <nct_id>NCT05116228</nct_id>
  </id_info>
  <brief_title>Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis in Low Disease Activity and Remission</brief_title>
  <acronym>REDOREM</acronym>
  <official_title>Randomized, Prospective, Active-comparator Controlled, Patient-blinded Study to Demonstrate Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis Patients in Low Disease Activity and Remission - the REDOREM Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether a reduced-dose dosing regimen (1x500mg semiannually) of rituximab&#xD;
      (RTX) (Mabthera®) is non-inferior in patients with rheumatoid arthritis (RA) whose disease is&#xD;
      in persistent low disease activity (LDA) or clinical remission (REM) (pLDA/pREM) as compared&#xD;
      to the standard dosing regimen of 1x1000mg semi-annual infusions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, controlled, single-centre study with 1x500mg or 1x1000 semi-annual infusions of&#xD;
      RTX (Mabthera) as intervention and a follow-up period of 2 years. Patients as well as&#xD;
      assessors will be blinded to the type of treatment. Patients in the 1x500mg group who&#xD;
      experience a flare as defined by the disease activity score 28-ESR (DAS28) will receive&#xD;
      1x1000mg RTX (Mabthera) at their upcoming scheduled infusion appointment. Patients in the&#xD;
      1x1000mg group whose disease activity reaches DAS28 &gt;3.2 during the duration of the study&#xD;
      will be re-evaluated for a change in biological therapy and will discontinue the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Failure to recruit&#xD;
  </why_stopped>
  <start_date>September 1, 2015</start_date>
  <completion_date type="Actual">November 1, 2021</completion_date>
  <primary_completion_date type="Actual">November 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of flare</measure>
    <time_frame>month 24</time_frame>
    <description>Disease activity score 28-Erythrocyte sedimentation sate (DAS28-ESR), Scale 0 (best) - 10 (worse)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression</measure>
    <time_frame>month 12</time_frame>
    <description>Sharp modified van der Heijde (SvdH) score, Scale 0 (best) - 488 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression</measure>
    <time_frame>month 24</time_frame>
    <description>Sharp modified van der Heijde (SvdH) score, Scale 0 (best) - 488 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical function</measure>
    <time_frame>months 12</time_frame>
    <description>Health assessment questionnaire disability index (HAQ-DI), Scale 0 (best) - 3.0 worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical function</measure>
    <time_frame>months 24</time_frame>
    <description>Health assessment questionnaire disability index (HAQ-DI), Scale 0 (best) - 3.0 worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of flare</measure>
    <time_frame>month 21</time_frame>
    <description>Disease activity score 28-Erythrocyte sedimentation sate (DAS28-ESR), Scale 0 (best) - 10 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of flare</measure>
    <time_frame>month 18</time_frame>
    <description>Disease activity score 28-Erythrocyte sedimentation sate (DAS28-ESR), Scale 0 (best) - 10 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of flare</measure>
    <time_frame>month 15</time_frame>
    <description>Disease activity score 28-Erythrocyte sedimentation sate (DAS28-ESR), Scale 0 (best) - 10 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of flare</measure>
    <time_frame>month 12</time_frame>
    <description>Disease activity score 28-Erythrocyte sedimentation sate (DAS28-ESR), Scale 0 (best) - 10 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of flare</measure>
    <time_frame>month 9</time_frame>
    <description>Disease activity score 28-Erythrocyte sedimentation sate (DAS28-ESR), Scale 0 (best) - 10 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of flare</measure>
    <time_frame>month 6</time_frame>
    <description>Disease activity score 28-Erythrocyte sedimentation sate (DAS28-ESR), Scale 0 (best) - 10 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of flare</measure>
    <time_frame>month 3</time_frame>
    <description>Disease activity score 28-Erythrocyte sedimentation sate (DAS28-ESR), Scale 0 (best) - 10 (worse)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Remission</condition>
  <arm_group>
    <arm_group_label>500mg RTX Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive 1x500mg (500mg RTX group) RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000mg RTX group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive 1x1000mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500mg RTX Group</intervention_name>
    <description>Patients will receive 1x500mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24</description>
    <arm_group_label>500mg RTX Group</arm_group_label>
    <other_name>Mabthera 500mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1000mg RTX Group</intervention_name>
    <description>Patients will receive 1x1000mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24</description>
    <arm_group_label>1000mg RTX group</arm_group_label>
    <other_name>Mabthera 1000mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of RA according to the 2010 American College of Rheumatology (ACR) /&#xD;
             European League Against Rheumatism (EULAR) classification criteria&#xD;
&#xD;
          -  Current treatment with RTX (at time of inclusion have already received at least 2&#xD;
             cycles of 1000mg RTX) at the Day-Clinic of the Division of Rheumatology of the Medical&#xD;
             University of Vienna&#xD;
&#xD;
          -  Persistent low disease activity or clinical remission as defined below&#xD;
&#xD;
          -  Persistent clinical remission (pREM) will be defined as a simplified disease activity&#xD;
             index (CDAI) (12) ≤2.8 measured at two time-points 6 months apart. The CDAI is&#xD;
             calculated as follows: tender joint count (TJC) + swollen joint count (SJC) +&#xD;
             patient's assessment of general health on a 100 mm visual analogue scale (GH) +&#xD;
             evaluator's assessment of general health on a 100 mm visual analogue scale (EGH)&#xD;
&#xD;
          -  Persistent low disease activity (pLDA) will be defined as a CDAI ≤10 measured at two&#xD;
             timepoints 6 months apart Patients who achieve REM at only either one of the two&#xD;
             successive time-points will be considered as having pLDA with regard to the current&#xD;
             trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients ≤ 18 yrs&#xD;
&#xD;
          -  Patients receiving RTX for a disease other than RA&#xD;
&#xD;
          -  Patients who fail to meet criteria for REM or LDA at either one of the two successive&#xD;
             timepoints (i.e. having a disease activity &gt;10 as measured by the clinical disease&#xD;
             activity index, (CDAI))&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Dr. Peter Mandl</investigator_full_name>
    <investigator_title>Co-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

